Topic: depressive disorders

Affective disorders, which can be categorized into depressive and bipolar disorders, represent a leading cause of disability worldwide. Despite their considerable prevalence, the intricate molecular and cellular mechanisms underlying these conditions remain elusive, mainly due to their complex etiologies and heterogeneous clinical presentations. Over the past years, the serotonergic system has emerged as a focal point in understanding the pathophysiological and therapeutic responses of affective disorders. Among the major regulators of this system, the serotonin transporter (SERT), which media

Depressive disorders are the leading cause of the neuropsychiatric disparity, and the lack of understanding of the causes and treatment of these disorders progresses toward therapeutic failure. Current treatment approaches only provide symptomatic relief but fail to cure the underlying pathophysiology. The present study aimed to investigate the antidepressant effect of escitalopram (ESC) and galantamine (GAL) combination in vivo on a chronic unpredictable mild stress (CUMS)-induced depression in mice and further explored its mechanism of action around cAMP, BDNF-related neurotrophic signaling,